Fig. 4. Multistep chemoenzymatic synthesis planning with minimal human intervention. Using our algorithm, we plan chemoenzymatic synthetic routes for (A) Sitagliptin (B) Rivastigmine (C) a key intermediate for angiotensin 1-converting enzyme inhibitors (D) Ephedrine (E) (R)-o-chloromandelic acid, (F) Rasagiline, and (G) S-Metalochlor. The suggested disconnections are consistent with published pathways.